Home Cart Sign in  
Chemical Structure| 262438-43-7 Chemical Structure| 262438-43-7

Structure of ATN-161
CAS No.: 262438-43-7

Chemical Structure| 262438-43-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ATN-161 is a five-amino-acid peptide derived from the synergy region of fibronectin and a beta integrin antagonist with antitumor activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ATN-161

CAS No. :262438-43-7
Formula : C23H35N9O8S
M.W : 597.64
SMILES Code : O=C(N)C[C@@H](C(N)=O)NC([C@H](CS)NC([C@H](CO)NC([C@H](CC1=CNC=N1)NC([C@H]2N(C(C)=O)CCC2)=O)=O)=O)=O
MDL No. :MFCD30478885
InChI Key :MMHDBUJXLOFTLC-WOYTXXSLSA-N
Pubchem ID :9960285

Safety of ATN-161

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ATN-161

cytoskeleton

Isoform Comparison

Biological Activity

Target
  • Integrin

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh7 cells 10 µMol/ml 24 hours Inhibited OCT4 mRNA expression J Transl Med. 2022 Dec 3;20(1):555.
VeroE6 cells 1 µM to 10 µM 1 hour To assess the ability of ATN-161 to inhibit SARS-CoV-2 infection. Results showed that ATN-161 increased cell viability at concentrations as low as 1 μM and reduced cytopathic effects at 10 μM. JACC Basic Transl Sci. 2021 Jan;6(1):1-8.
DU145 prostate cancer cells 1 μg/ml 24 hours To evaluate the inhibitory effect of PHSCN peptide on the invasive ability of DU145 cells. Results showed that PHSCN peptide significantly reduced the invasive ability of DU145 cells, with a six-fold decrease compared to untreated cells. Neoplasia. 2002 Sep-Oct;4(5):373-9.
HCCLM3 cells 10 µMol/ml 24 hours Inhibited NANOG and OCT4 mRNA expression, reduced YAP activation J Transl Med. 2022 Dec 3;20(1):555.
Human aortic endothelial cells (HAECs) 50 µM 30 minutes To evaluate the effect of ATN-161 on shear stress-induced endothelial cell activation. Results showed that ATN-161 did not affect shear stress-induced activation of FAK, PAK2, and NF-κB. Am J Pathol. 2015 Sep;185(9):2575-89.
HEK293T-ACE2 cells 0.1 mM 6 hours Investigate the effect of ATN-161 on rVSV-S infection, results showed that ATN-161 exhibited no inhibition effect on rVSV-S infection Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2311913120.
Human aortic endothelial cells (HAEC) 100 μg/mL 6 hours Evaluate VCAM-1 and ICAM-1 protein expression Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1362-73.
Human aortic endothelial cells (HAEC) 100 μg/mL 6 hours Evaluate oxLDL-induced monocyte adhesion Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1362-73.
Adult tenocytes 100 µM 60 minutes To study the effect of ATN-161 on Pro-Hyp uptake, results showed ATN-161 significantly inhibited Pro-Hyp uptake J Biol Chem. 2021 Jul;297(1):100819.
BEnd.3 cells 5, 10, 25, and 50 µM 6hours OGD/24hours reoxygenation ATN-161 effectively inhibited OGD/R-induced integrin α5, NLRP3 inflammasome, oxidative stress, mitochondrial damage, fibrosis, and tight junction protein loss. Inflammation. 2021 Dec;44(6):2377-2394.
Human aortic endothelial cells (HAEC) 100 μg/mL indicated times Evaluate VCAM-1 and ICAM-1 mRNA expression Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1362-73.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CD4/H11001CD45RBhigh T-cell transfer colitis model Intraperitoneal injection 1 mg/kg Three times a week for six weeks ATN-161 significantly reduced histopathological scores and angiogenic index in CD4/H11001CD45RBhigh colitis, indicating its therapeutic effect by inhibiting angiogenesis during experimental colitis. Am J Pathol. 2006 Dec;169(6):2014-30
Mice IL10-deficient mice and DSS-induced colitis model Intraperitoneal injection 1 mg/kg Every other day for 6 weeks To evaluate the therapeutic effect of ATN-161 on experimental colitis. Results showed that ATN-161 significantly reduced the Disease Activity Index (DAI), histological colitis score, and mean vascular density (MVD), and decreased the production of inflammatory cytokines. Gut. 2007 Jun;56(6):855-62
K18-hACE2 transgenic mice SARS-CoV-2 infection model Intravenous injection 1 mg/kg Single or repeated doses within 48 hours post-infection Reduced lung viral load, viral immunofluorescence, and improved lung histology Life Sci. 2021 Nov 1;284:119881
Mice Ischemic stroke model Intraperitoneal injection 1 mg/kg Immediately after reperfusion, on post-stroke day (PSD)1 and PSD2 To evaluate the therapeutic effects of ATN-161 on ischemic stroke, results showed ATN-161 significantly reduced infarct volume, edema, and functional deficits, while also reducing BBB permeability and inflammatory responses J Cereb Blood Flow Metab. 2020 Aug;40(8):1695-1708
BALB/c mice Colorectal cancer liver metastasis model Intraperitoneal injection 1 mg/kg Every two days ATN-161 inhibits tumor metastasis Int J Mol Sci. 2023 Nov 6;24(21):16001
Mice Stroke model Intraperitoneal injection 1 mg/kg Single dose To test whether combination treatment of ATN-161 with hNSC transplantation further benefits stroke outcome. Results showed that ATN-161 combined with hNSC transplantation reduced infarct size and attenuated the induction of proinflammatory factors and matrix metalloproteases. Exp Neurol. 2022 Jan;347:113913
ApoE knockout mice Atherosclerosis model Intraperitoneal injection 5 mg/kg Three times per week for 7 days To evaluate the effect of ATN-161 on atherosclerotic plaque formation. Results showed that ATN-161 did not affect plaque formation or inflammatory responses. Am J Pathol. 2015 Sep;185(9):2575-89.
ApoE-deficient mice High-fat Western Diet-induced atherosclerosis model Intraperitoneal injection 5 mg/kg Three times a week for 8 weeks Evaluate the effect of ATN-161 on atherosclerotic plaque development Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1362-73.
Athymic nude mice DU145 prostate cancer xenograft model Intravenous injection 50 mg/kg Three times per week, continued until the end of the experiment To evaluate the inhibitory effect of PHSCN peptide on DU145 tumor recurrence and metastasis. Results showed that PHSCN peptide significantly inhibited tumor recurrence and metastasis, with all treated mice remaining recurrence- and metastasis-free for 30 weeks post-surgery. Neoplasia. 2002 Sep-Oct;4(5):373-9.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00131651 Carcinoma, Renal Cell PHASE2 TERMINATED - University of California Irvin... More >>e, Chao Family Comprehensive Cancer Center, Irvine, California, 92868, United States|University of California San Francisco Comprehensive Cancer Center, San Francisco, California, 94115, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44165, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, 53792-6164, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.37mL

1.67mL

0.84mL

16.73mL

3.35mL

1.67mL

References

 

Historical Records

Categories